After a median follow-up of 14.4 months, the men who had Xtandi along with ADT experienced an improved radiographic progression-free survival advantage over those who had only ADT, regardless of their prior treatment.
Findings confirm the better strategy for salvage therapy after failed surgery for prostate cancer is ADT along with radiotherapy,
The trial found that 80% of men with metastatic hormone-sensitiveprostate cancer who received enzalutamide (Xtandi) along with standard-of-care treatment (ADT) were alive after three years, compared with just 72% of men who received other nonsteroidal antiandrogens along with standard ADT therapy.
A recent finding shows that men with a Gleason score of 9–10 prostate cancer may derive a smaller survival benefit from androgen deprivation therapy (ADT) compared with those with Gleason score of 8.
Why are Zytiga and Xtandi added to ADT and not substituted for ADT? Do I really need to continue ADT when I use Xtandi or Zytiga?
Hormone Therapy (ADT) along with the chemotherapy drug Taxotere (docetaxel) and Estramustine improves survival in men with high risk, localized castration-resistant prostate cancer over ADT alone.
We know that the incidence of both cardiovascular disease (CVD) and prostate cancer increase with age, resulting in higher mortality. CVD is the second most common cause of death in men with prostate cancer [1,2] Hormone therapy (ADT) with gonadotropin-releasing hormone (GnRH) agonists like Lupron for treatment of prostate cancer has been linked to additional increases in CVD morbidity and mortality. This link is especially evident in the first year of treatment , and men with a history of CVD are at higher risk .
Degarelix, which is different from the (GnRH) agonists, is a GnRH receptor antagonist also approved for the treatment of men with advanced prostate cancer. However, good data is suggesting that degarelix might have a lower incidence of causing CVD than the GnRH agonists
What is the proper target level for your testosterone to be considered castrate when you are on ADT?
Through the work of Huggins et al.  in 1941, it was shown that metastatic prostate cancer responds positively to an orchiectomy (surgical castration). We now know that there isn’t any other therapy which produces a more reliable regression of both distant and local disease than androgen withdrawal (ADT).
Continuous long-term ADT significantly reduces the sensitivity and visibility of castration-sensitive prostate cancer on PSMA PET/CT scans.
Metformin is an inexpensive drug that might be able to be used with men with advanced prostate cancer who are on hormone therapy (ADT).
Why doesn’t someone newly diagnosed with prostate cancer automatically receive chemotherapy along with hormone therapy (ADT)? There is a good reason.
Having positive lymph node metastasis (LNM or pN1) after a radical prostatectomy (RP) to treat prostate cancer is a poor prognostic indicator. Knowing what the next best course of treatment is if you are in this situation remains questionable. To begin to understand and better answer this problem a group of researchers performed a comparative analysis of three of the current management strategies for men with positive lymph nodes after RP.
A study found that African American men had a higher rate of death from non-prostate cancer problems than non-African American men after receiving short-term hormone therapy (ADT) prior to having brachytherapy (seeds). There are significant implications beyond this research for African Americans using ADT for any purpose, including he treatment of advanced (progressive) prostate cancer.
Becoming castrate resistant is a significant turn of events for men with advanced prostate cancer. Before you accept this new diagnosis make sure that you confirm its validity.
Two game changing trials demonstrated that the early use of Zytiga along with hormone therapy (ADT) can provide a significant survival advantage for men with aggressive, hormone naive prostate cancer. The data is very clear for men with metastatic disease, but there remains some controversy if this holds up for men who are not metastatic.
Analyses showed that there is a statistically significant survival advantages for men who had a low baseline testosterone level prior to starting ADT.